Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of Dental Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pinsky, M.S.
Right arrow Articles by Nör, J.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinsky, M.S.
Right arrow Articles by Nör, J.E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Activation of iCaspase-9 in Neovessels Inhibits Oral Tumor Progression

M.S. Pinsky1,2, W. Song1, Z. Dong1, K. Warner1, B. Zeitlin1, E. Karl1, D.E. Hall3 and J.E. Nör1,*

1 Angiogenesis Research Laboratory, Department of Cariology, Restorative Sciences, and Endodontics, and
2 Department of Oral and Maxillofacial Surgery, University of Michigan School of Dentistry, 1011 N. University, Rm. 2309, Ann Arbor, MI 48109-1078, USA; and
3 Center for Molecular Imaging, Department of Radiology, University of Michigan School of Medicine, Ann Arbor


Figure 1
View larger version (100K):
[in this window]
[in a new window]

  		Figure 1. Activation of iCaspase-9 in neovascular endothelial cells is sufficient to decrease tumor microvessel density. (A) Graph depicting the number of microvessels in tumors populated with OSCC-3 (oral squamous cell carcinoma cells) and stably transduced HDMEC-iCasp-9 or control cells (HDMEC-LXSN) retrieved from mice treated with 3 consecutive daily intraperitoneal injections of 2 mg/kg AP20187. Each mouse received one scaffold seeded with HDMEC-iCasp-9 + OSCC-3, and one control scaffold seeded with HDMEC-LXSN + OSCC-3. We evaluated 5 tumors from 5 independent mice per condition, and the data presented in the graph represent mean values (± SD) of 10 microscopic fields per tumor. Statistical significance (asterisk) was determined at p ≤ 0.05, with the microvessel density for the HDMEC-LXSN group used as control. (B,C) Photomicrographs of representative histological sections depicting immunochemistry with Factor VIII antibody to identify blood vessels (arrows). Tumor microvessels are relatively small and can be identified only by immunohistochemistry, presumably due to the rapid growth of xenografted OSCC-3 tumors (scale bar, 50 µm for B-C).

 

Figure 2
View larger version (80K):
[in this window]
[in a new window]

  		Figure 2. Characterization of luciferase expressing squamous cell carcinoma cells by in vivo bioluminescence. (A) Luciferase activity of two clones of UM-SSC-17B-luc and controls, i.e., UM-SCC-17B-neo (transduced with empty vector), or substrate only without cells (-). Cells were seeded in six-well plates (50,000 cells/well, triplicate wells/condition) and cultured for 48 hrs. Statistical significance (asterisk) was determined at p ≤ 0.05, with the luciferase activity obtained for the UM-SCC-17B-neo cells used as control. (B) Luciferase activity of 0-100,000 UM-SSC-17B-luc (M2) cells cultured for 48 hrs in six-well plates (triplicate wells/condition), demonstrating that the intensity of bioluminescence in vitro is directly correlated to the number of cells. Statistical significance was determined at p ≤ 0.05, with the baseline luciferase activity obtained for substrate only (no cells) used as control. (C,D) Determination of saturation times for in vivo bioluminescence imaging of 1 representative mouse (N = 1) that received 1 scaffold containing HDMEC-iCasp-9 and OSCC3-luc (lower, righthand side), and 1 scaffold containing HDMEC-LXSN and OSCC3-luc (upper, lefthand side). This mouse was treated with 2 mg/kg AP20187 for 3 consecutive days. Images were acquired 1–16 min post-injection of luciferin. The graph presented in panel (C) depicts a time-course for bioluminescence intensity after injection of luciferin in the mouse depicted in panel (D). (E) In vivo bioluminescence imaging of 1 representative mouse (N = 1) bearing a xenografted tumor (HDMEC-LXSN and OSCC-3-luc) from day 14 through day 35 post-implantation, for evaluation of luciferase expression over time.

 

Figure 3
View larger version (83K):
[in this window]
[in a new window]

  		Figure 3. In vivo bioluminescence analysis of the effect of iCaspase-9 activation on tumor progression. (A) Representative images of mice injected with either Ad-iCaspase-9 (no promoter) or Ad-VEGFR2-iCaspase-9 (with endothelial cell-specific promoter), and treated with either the dimerizer drug AP20187 (2 mg/kg) or the negative control phosphate-buffered saline (PBS) solution. In vivo bioluminescence imaging was performed 3 days after tumor implantation (baseline), 20 days post-implantation (day of adenovirus injection), 21 days post-implantation (just prior to treatment with AP20187), and 25 days post-implantation (just prior to death). (B–E) Each graph depicts, presented in the left side of this Fig. (panel A), the quantification of bioluminescence over time for the corresponding mouse (N = 1).

 

Figure 4
View larger version (31K):
[in this window]
[in a new window]

  		Figure 4. Tumor progression is inhibited by intratumoral injection of the adenovirus Ad-VEGFR2-iCasp9 and administration of AP20187. (A) Graph depicting bioluminescence values (± SD) of mice bearing tumors (UM-SCC-17B-luc cells) injected with either Ad-VEGFR2-iCasp-9 or Ad-iCasp-9 (no promoter control), and treated with either 2 mg/kg AP20187 or negative control phosphate-buffered saline (PBS). Statistical significance (asterisk) was determined at p ≤ 0.05, with the bioluminescence values obtained for the Ad-iCasp-9 + PBS group in each individual time point used as controls. (B) Graph demonstrating the percent change in bioluminescence from day 21 (beginning of treatment with AP20187) to day 25 (death). Statistical significance was determined at p ≤ 0.05, with the bioluminescence values obtained for the Ad-VEGFR2-iCasp-9 + PBS group as control. We evaluated 5 tumors per condition from 5 independent mice, and the data presented in the graphs (panels A and B) represent mean values (± SD) of 10 microscopic fields per tumor. (C,D) Photomicrographs of representative histological sections after immunochemistry with Factor VIII antibody to identify tumor blood vessels (arrows). Tumors (UM-SCC-17B-luc) were retrieved from mice that received Ad-VEGFR2-iCaspase-9, and were treated with either PBS (C) or 2 mg/kg AP20187 (D) (scale bar, 50 µm for C–D).

 

Journal of Dental Research, Vol. 85, No. 5, 436-441 (2006)
DOI: 10.1177/154405910608500508
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?